Intellectual Property
Overview
Protecting business assets and navigating the complexity
All businesses from SMEs to global companies must understand and protect their IP rights if they are to maintain their market value. For some companies, the most important issues will involve brand protection or the protection of trade secrets. Others may need to protect their copyrights, and still others, such as those that rely heavily on technology and scientific research, must navigate the complexities of patents and supplementary protection certificates.
Our Brussels IP practice is one of the largest, strongest, and most diverse in Belgium and is ranked in Band 1 for Intellectual Property - Belgium by Chambers Europe. We assist clients from a broad range of industries and we are well-known for our advisory and dispute resolution skills, especially in complex, multi-jurisdictional matters. Our creative thinking combines with a tough, no-nonsense approach to litigation and this helps protect our clients both in and outside the courtroom.
Thanks to our cutting-edge tech abilities, we are able to help clients negotiate software license agreements, collaborative IT development agreements, outsourcing and other IT service agreements, and confidentiality and non-disclosure agreements.
Insights
Client Alert | 5 min read | 06.24.24
The Judgment of the Brussels Court of Appeal is the latest development in the saga in Belgium where a Belgian parallel importer, PI Pharma NV, imported a generic Sandoz product from the Netherlands, repackaged and rebranded them, and placed them on the Belgian market alleging they were a Novartis’ originator product.
Client Alert | 22 min read | 05.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations – UPDATED in May 2024
Press Coverage | 04.15.24
L’IA et le monde juridique: “Les cabinets qui n’utilisent pas l’IA vont disparaître”
Firm News | 3 min read | 04.01.24
Insights
Client Alert | 5 min read | 06.24.24
The Judgment of the Brussels Court of Appeal is the latest development in the saga in Belgium where a Belgian parallel importer, PI Pharma NV, imported a generic Sandoz product from the Netherlands, repackaged and rebranded them, and placed them on the Belgian market alleging they were a Novartis’ originator product.
Client Alert | 22 min read | 05.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations – UPDATED in May 2024
Press Coverage | 04.15.24
L’IA et le monde juridique: “Les cabinets qui n’utilisent pas l’IA vont disparaître”
Firm News | 3 min read | 04.01.24
Insights
Client Alert | 5 min read | 06.24.24
The Judgment of the Brussels Court of Appeal is the latest development in the saga in Belgium where a Belgian parallel importer, PI Pharma NV, imported a generic Sandoz product from the Netherlands, repackaged and rebranded them, and placed them on the Belgian market alleging they were a Novartis’ originator product.
Client Alert | 22 min read | 05.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations – UPDATED in May 2024
Press Coverage | 04.15.24
L’IA et le monde juridique: “Les cabinets qui n’utilisent pas l’IA vont disparaître”
Firm News | 3 min read | 04.01.24